mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma

Opinion statement Head and neck squamous cell carcinomas (HNSCC) represent 6% of all cancers diagnosed each year in the United States, affecting approximately 43,000 new patients and resulting in approximately 12,000 deaths. Currently, three main rapalogs exist for the treatment of cancer: CCI-779 (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current treatment options in oncology 2012-03, Vol.13 (1), p.71-81
Hauptverfasser:	Nguyen, Shaun A., Walker, David, Gillespie, M. Boyd, Gutkind, J. Silvio, Day, Terry A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacokinetics Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - epidemiology Carcinoma, Squamous Cell - genetics Clinical Trials as Topic Everolimus Female Head and Neck Cancer (T Day Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - epidemiology Head and Neck Neoplasms - genetics Humans Male Medicine Medicine & Public Health Oncology Section Editor Signal Transduction Sirolimus - analogs & derivatives Sirolimus - pharmacokinetics TOR Serine-Threonine Kinases - antagonists & inhibitors United States - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!